OKYO Pharma ’s Post

One week, two different continents 🌎 Join us in Denmark and South Korea for two much awaited events! 📍2024 PDA Parenteral Packaging Conference: 23 – 24 April,   Copenhagen, Denmark 🇩🇰  📍 Cophex 2024: 23 – 26 April, Goyang, South Korea 🇰🇷 Explore the future of pharma, packaging and biotech at these industry leading events and discover cutting-edge solutions that are sure to disrupt the industry’s paradigm and trigger innovation in your company. Whether it be in Denmark or South Korea, come meet our experts to learn about the latest pharma trends, discusse your company’s challenges and how we can help you move forward. Don’t miss on this chance! 🙌 Discover more about these events and, if you can’t meet us this week, check Körber Pharma’s upcoming events 👉 https://lnkd.in/dBdWwXR9 #cophex2024 #PDA #pharma #pharmaindustry #KörberPharma  

Two Members of GBI have participated in Pharma's Almanac's RoundTable discussions! 💬 ✍ 👀 Click the link below to read Amita Quadros, VP of Commercial Operations, response to "What Do you Think was the Single Most Consequential Event or Result in Parma/Biopharma in 2023?" https://lnkd.in/efh3Qphx Click the link below to read Muctarr Sesay, CSO and VP of Bioconjugation, response to "What do you see as the most significant regulatory decision or guidance on the horizon for 2024 (or beyond)?" https://lnkd.in/e4ydQBRv #biotech #cdmo #roundtablediscussion #2024predictions

ANNOUNCEMENT: After a long planning period, I am excited that it is now possible to invite you to the 2024 Pharma Theme Day at Siemens in Ballerup.   At the event we have designed an agenda, that are focusing on the challenges related to Pharmaceutical Manufacturing, and how technology can help solve those challenges. The agenda will be a combination of presentation and an exhibition area. There will be Siemens and external keynote speakers, presenting the different topics, and there will also be a panel discussion about “Digital Twin” in pharmaceutical manufacturing, and during the breaks there will be and exhibition, where it will be possible to have dialogue about the different topics and other related topics towards Pharmaceutical Manufacturing.    I therefore hope that you can find time in your schedule to participate in the Theme Day which are taking place 10. Of September 2024 Below you can see some details about the Themeday and in the link you can sign up for the event.   Sign up for the event at the Official Theme Day website:  www.siemens.dk/pharmaday24 #Siemens #GMP #Pharmaceutical #DigitalTwin #Automation #software #Technology

🔴Attention: The social media post copy requested is based on an article from Forbes titled "Ozempic Maker Novo Nordisk Sinks On Disappointing Earnings". Here's the localized social media post for crossposting on LinkedIn: --- 🚀 Breaking news alert! Forbes just reported on Novo Nordisk's latest earnings, and the results have made waves. As the maker of Ozempic, Novo Nordisk has shown significant volatility in response to its financial performance. This development underscores the dynamic landscape of the pharmaceutical industry and the impact on key players. Understanding these shifts is crucial for industry professionals and investors alike. Check out the full article for valuable insights and analysis. #NovoNordisk #Ozempic #PharmaNews Read the full Forbes article here: [insert link] --- https://ift.tt/vyUi5Ch

Looking forward to attending the Biopharma & Life Sciences Connected Live Conference next week. There is a great line-up of speakers throughout the day and interesting topics will be discussed. What are the challenges and trends that we will see in the future of Biopharma? #InnoGlobal #BiopharmaLifeScience #Innovation #Manufacturing #Conference

With a surge in M&A activity and partnering approaches returning to pre-pandemic levels, the biopharma dealmaking environment is showing signs of life in 2024. What trends do you think will shape the future of biopharma dealmaking? https://ow.ly/vXv830sCWLb #Biopharma #DealMaking #MA #Innovation #HealthcareTrends

European biotech and pharma companies who do business in the US market (or may be in the future), may be wondering about the complexities of the Inflation Reduction Act and its impact. Join Director Deborah Sterling at the 10th LSX World Congress on April 29 in London when she moderates the panel "The Inflation Reduction Act and its Potential Impact On EU Biotech & Pharma Companies: Demystifying the Future." Learn more: https://lnkd.in/eBBQwUPN 🔍 The panel will discuss the long-term implications for EU companies looking to grow in the US and what biotechs and investors need to consider to leverage future success. You don’t want to miss this insightful discussion! #LSXWorldCongress #Biotech #Pharma

📈 The latest article from Nature Portfolio reveals a remarkable surge in #China’s innovative #drug R&D, with a near doubling of products in the #pipeline since 2021. 🚀 In 2023 alone, China saw the approval of 30 new medicines, showcasing a strong commitment to #healthcareinnovation. What’s more impressive is the growth in first-in-class and fast-follower agents, indicating a rapid pace of development that’s catching up with global standards. 🧬 The future looks bright, with next-generation #therapies like #celltherapies and #genetherapies, and bi-specific #antibodies leading the charge. #externalinnovation #pharmainnovation #biotechinnovation #biopharmainnovation #pharmaceuticalinnovation #pharmatrends #pharmaRnD #healthcare doi:

With a surge in M&A activity and partnering approaches returning to pre-pandemic levels, the biopharma dealmaking environment is showing signs of life in 2024. What trends do you think will shape the future of biopharma dealmaking? https://ow.ly/KFXi30sCT3U #Biopharma #DealMaking #MA #Innovation #HealthcareTrends

🚀 Exciting Updates Ahead! 🚀 Daniel Chancellor and Isma Hachi, PhD have been working on a series of teasers leading up to their speaking session, “Knowing Me, Knowing You: A Tête-à-Tête on Global Trends and the Next Wave of Biopharma Innovation” on November 4th at 1 PM CET at BIO-Europe. In this first teaser, we dive into key insights on the global biopharma pipeline. Here’s a snapshot of what’s happening in the industry: 1️⃣ Asset growth continues strong, with a 7% increase in 2023, bringing the total to around 23,000 assets. 2️⃣ There are now over 10,000 clinical-stage drugs in the pipeline. 3️⃣ Phase III trials have crossed the 1,000-mark milestone. 4️⃣ China and drug platforms are driving the majority of growth. 5️⃣ Europe’s share of the pipeline has dropped from 45% to 22% over the last 15 years. 6️⃣ Products from China-headquartered companies now account for 29% of the R&D pipeline—up from 16% five years ago, and just 1% in 2008! 7️⃣ The US share has fallen from 42% to 34% in the same period, though the absolute number of trials remains stable (1,707 in 2008 vs. 1,704 in 2023). 💡 Have questions you’d like us to cover during the BioEurope session? Drop them in the comments below, and we’ll address them during the event! And this is just the beginning! More insights are coming your way in the weeks ahead. Stay tuned for the next teaser! #BioEurope #Biopharma #Innovation #EBDGroup #Norstella #IQVIA